Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HORIZON-SWITCH-SZ: Zovaglutide Switch Study in Adults With Obesity
NCT07812597Phase 2Not yet recruiting
- Sponsor
- QL Biopharm
- Start
- Oct 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zovaglutide in obesity (3 arms), sponsored by QL Biopharm. Primary endpoint: Proportion of participants achieving successful switch from semaglutide 2.4 mg to zovaglutide after randomization at 16 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
zovaglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07812597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07812597.